Do analysts prefer HUMA or AVTE?

Humacyte currently has a consensus price target of $6.25, indicating a potential upside of 823.19%. Given Humacyte's stronger consensus rating and higher possible upside, analysts clearly believe Humacyte is more favorable than Aerovate Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Humacyte 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.75 Aerovate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better earnings and valuation, HUMA or ALT?

Humacyte has higher revenue and earnings than Altimmune. Altimmune is trading at a lower price-to-earnings ratio than Humacyte, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Humacyte $2.04M 73.68 -$40.83M -$0.57 N/A Altimmune $40K 14,512.32 -$88.09M -$0.93 N/A

Is HUMA or ALT more profitable?

Humacyte has a net margin of -4,836.06% compared to Altimmune's net margin of -214,860.98%. Altimmune's return on equity of -42.57% beat Humacyte's return on equity. Company Net Margins Return on Equity Return on Assets Humacyte -4,836.06% -2,914.18% -89.45% Altimmune -214,860.98% -42.57% -35.57%

Does the media favor HUMA or ALT?

In the previous week, Humacyte and Humacyte both had 3 articles in the media. Humacyte's average media sentiment score of 1.38 beat Altimmune's score of 0.71 indicating that Humacyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Humacyte 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Altimmune 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, PROK or HUMA?

Humacyte has higher revenue and earnings than ProKidney. ProKidney is trading at a lower price-to-earnings ratio than Humacyte, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ProKidney $890K 537.94 -$68.99M -$0.53 N/A Humacyte $2.04M 73.68 -$40.83M -$0.57 N/A

Is PROK or HUMA more profitable?

Humacyte has a net margin of -4,836.06% compared to ProKidney's net margin of -8,131.50%. ProKidney's return on equity of 0.00% beat Humacyte's return on equity. Company Net Margins Return on Equity Return on Assets ProKidney -8,131.50% N/A -21.39% Humacyte -4,836.06% -2,914.18% -89.45%

Does the media prefer PROK or HUMA?

In the previous week, Humacyte had 1 more articles in the media than ProKidney. MarketBeat recorded 3 mentions for Humacyte and 2 mentions for ProKidney. Humacyte's average media sentiment score of 1.38 beat ProKidney's score of 0.94 indicating that Humacyte is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ProKidney 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Humacyte 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend HUMA or ZSQR?

Humacyte presently has a consensus target price of $6.25, suggesting a potential upside of 823.19%. Given Humacyte's stronger consensus rating and higher probable upside, research analysts clearly believe Humacyte is more favorable than Coeptis Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Humacyte 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.75 Coeptis Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media refer more to CTNM or HUMA?

In the previous week, Humacyte had 1 more articles in the media than Contineum Therapeutics. MarketBeat recorded 3 mentions for Humacyte and 2 mentions for Contineum Therapeutics. Contineum Therapeutics' average media sentiment score of 1.43 beat Humacyte's score of 1.38 indicating that Contineum Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Contineum Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Humacyte 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Humacyte (HUMA) Competitors

$0.68 -0.01 (-2.05%)

As of 09:38 AM Eastern

Compare

HUMA vs. AVTE, ALT, PROK, ZSQR, and CTNM

Should you buy Humacyte stock or one of its competitors? MarketBeat compares Humacyte with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Humacyte include Aerovate Therapeutics (AVTE), Altimmune (ALT), ProKidney (PROK), Coeptis Therapeutics (ZSQR), and Contineum Therapeutics (CTNM). These companies are all part of the "pharmaceutical products" industry.

How does Humacyte compare to Aerovate Therapeutics?

Humacyte (NASDAQ:HUMA) and Aerovate Therapeutics (NASDAQ:AVTE) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, analyst recommendations, valuation, media sentiment and institutional ownership.

Humacyte has higher revenue and earnings than Aerovate Therapeutics. Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Humacyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Humacyte	$2.04M	73.68	-$40.83M	-$0.57	N/A
Aerovate Therapeutics	N/A	N/A	-$75.52M	-$1.70	N/A

44.7% of Humacyte shares are owned by institutional investors. 3.1% of Humacyte shares are owned by company insiders. Comparatively, 24.9% of Aerovate Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Humacyte currently has a consensus price target of $6.25, indicating a potential upside of 823.19%. Given Humacyte's stronger consensus rating and higher possible upside, analysts clearly believe Humacyte is more favorable than Aerovate Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Humacyte	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Aerovate Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Aerovate Therapeutics has a net margin of 0.00% compared to Humacyte's net margin of -4,836.06%. Aerovate Therapeutics' return on equity of -90.19% beat Humacyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Humacyte	-4,836.06%	-2,914.18%	-89.45%
Aerovate Therapeutics	N/A	-90.19%	-77.47%

In the previous week, Humacyte had 3 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 3 mentions for Humacyte and 0 mentions for Aerovate Therapeutics. Humacyte's average media sentiment score of 1.38 beat Aerovate Therapeutics' score of 0.00 indicating that Humacyte is being referred to more favorably in the media.

Company	Overall Sentiment
Humacyte	Positive
Aerovate Therapeutics	Neutral

Humacyte has a beta of 2.52, meaning that its stock price is 152% more volatile than the broader market. Comparatively, Aerovate Therapeutics has a beta of 0.95, meaning that its stock price is 5% less volatile than the broader market.

Summary

Humacyte beats Aerovate Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Humacyte compare to Altimmune?

Humacyte (NASDAQ:HUMA) and Altimmune (NASDAQ:ALT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, dividends, analyst recommendations, profitability, earnings, valuation and risk.

In the previous week, Humacyte and Humacyte both had 3 articles in the media. Humacyte's average media sentiment score of 1.38 beat Altimmune's score of 0.71 indicating that Humacyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Humacyte	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Altimmune	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Humacyte presently has a consensus target price of $6.25, indicating a potential upside of 823.19%. Altimmune has a consensus target price of $15.71, indicating a potential upside of 426.44%. Given Humacyte's stronger consensus rating and higher possible upside, analysts clearly believe Humacyte is more favorable than Altimmune.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Humacyte	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Altimmune	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

Humacyte has higher revenue and earnings than Altimmune. Altimmune is trading at a lower price-to-earnings ratio than Humacyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Humacyte	$2.04M	73.68	-$40.83M	-$0.57	N/A
Altimmune	$40K	14,512.32	-$88.09M	-$0.93	N/A

44.7% of Humacyte shares are owned by institutional investors. Comparatively, 78.1% of Altimmune shares are owned by institutional investors. 3.1% of Humacyte shares are owned by company insiders. Comparatively, 1.6% of Altimmune shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Humacyte has a net margin of -4,836.06% compared to Altimmune's net margin of -214,860.98%. Altimmune's return on equity of -42.57% beat Humacyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Humacyte	-4,836.06%	-2,914.18%	-89.45%
Altimmune	-214,860.98%	-42.57%	-35.57%

Humacyte has a beta of 2.52, indicating that its share price is 152% more volatile than the broader market. Comparatively, Altimmune has a beta of 0.25, indicating that its share price is 75% less volatile than the broader market.

Summary

Humacyte beats Altimmune on 10 of the 15 factors compared between the two stocks.

How does Humacyte compare to ProKidney?

ProKidney (NASDAQ:PROK) and Humacyte (NASDAQ:HUMA) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, media sentiment, dividends, earnings, valuation and risk.

In the previous week, Humacyte had 1 more articles in the media than ProKidney. MarketBeat recorded 3 mentions for Humacyte and 2 mentions for ProKidney. Humacyte's average media sentiment score of 1.38 beat ProKidney's score of 0.94 indicating that Humacyte is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ProKidney	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Humacyte	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Humacyte has higher revenue and earnings than ProKidney. ProKidney is trading at a lower price-to-earnings ratio than Humacyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProKidney	$890K	537.94	-$68.99M	-$0.53	N/A
Humacyte	$2.04M	73.68	-$40.83M	-$0.57	N/A

51.6% of ProKidney shares are owned by institutional investors. Comparatively, 44.7% of Humacyte shares are owned by institutional investors. 39.8% of ProKidney shares are owned by company insiders. Comparatively, 3.1% of Humacyte shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

ProKidney has a beta of 1.61, meaning that its stock price is 61% more volatile than the broader market. Comparatively, Humacyte has a beta of 2.52, meaning that its stock price is 152% more volatile than the broader market.

ProKidney currently has a consensus price target of $10.00, indicating a potential upside of 530.91%. Humacyte has a consensus price target of $6.25, indicating a potential upside of 823.19%. Given Humacyte's stronger consensus rating and higher probable upside, analysts clearly believe Humacyte is more favorable than ProKidney.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProKidney	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Humacyte	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

Humacyte has a net margin of -4,836.06% compared to ProKidney's net margin of -8,131.50%. ProKidney's return on equity of 0.00% beat Humacyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ProKidney	-8,131.50%	N/A	-21.39%
Humacyte	-4,836.06%	-2,914.18%	-89.45%

Summary

Humacyte beats ProKidney on 10 of the 17 factors compared between the two stocks.

How does Humacyte compare to Coeptis Therapeutics?

Humacyte (NASDAQ:HUMA) and Coeptis Therapeutics (NASDAQ:ZSQR) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, profitability and analyst recommendations.

44.7% of Humacyte shares are held by institutional investors. Comparatively, 13.9% of Coeptis Therapeutics shares are held by institutional investors. 3.1% of Humacyte shares are held by insiders. Comparatively, 24.3% of Coeptis Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Humacyte had 2 more articles in the media than Coeptis Therapeutics. MarketBeat recorded 3 mentions for Humacyte and 1 mentions for Coeptis Therapeutics. Coeptis Therapeutics' average media sentiment score of 1.89 beat Humacyte's score of 1.38 indicating that Coeptis Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Humacyte	Positive
Coeptis Therapeutics	Very Positive

Humacyte has a beta of 2.52, indicating that its share price is 152% more volatile than the broader market. Comparatively, Coeptis Therapeutics has a beta of -0.25, indicating that its share price is 125% less volatile than the broader market.

Humacyte presently has a consensus target price of $6.25, suggesting a potential upside of 823.19%. Given Humacyte's stronger consensus rating and higher probable upside, research analysts clearly believe Humacyte is more favorable than Coeptis Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Humacyte	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Coeptis Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Coeptis Therapeutics has lower revenue, but higher earnings than Humacyte. Coeptis Therapeutics is trading at a lower price-to-earnings ratio than Humacyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Humacyte	$2.04M	73.68	-$40.83M	-$0.57	N/A
Coeptis Therapeutics	$1.36M	283.24	-$11.92M	-$2.52	N/A

Coeptis Therapeutics has a net margin of -810.04% compared to Humacyte's net margin of -4,836.06%. Coeptis Therapeutics' return on equity of -92.29% beat Humacyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Humacyte	-4,836.06%	-2,914.18%	-89.45%
Coeptis Therapeutics	-810.04%	-92.29%	-73.52%

Summary

Humacyte beats Coeptis Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Humacyte compare to Contineum Therapeutics?

Contineum Therapeutics (NASDAQ:CTNM) and Humacyte (NASDAQ:HUMA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, earnings, valuation, media sentiment, profitability and analyst recommendations.

Contineum Therapeutics has a net margin of 0.00% compared to Humacyte's net margin of -4,836.06%. Contineum Therapeutics' return on equity of -27.09% beat Humacyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Contineum Therapeutics	N/A	-27.09%	-25.64%
Humacyte	-4,836.06%	-2,914.18%	-89.45%

Contineum Therapeutics presently has a consensus price target of $20.00, suggesting a potential upside of 34.68%. Humacyte has a consensus price target of $6.25, suggesting a potential upside of 823.19%. Given Humacyte's stronger consensus rating and higher possible upside, analysts plainly believe Humacyte is more favorable than Contineum Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Contineum Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Humacyte	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, Humacyte had 1 more articles in the media than Contineum Therapeutics. MarketBeat recorded 3 mentions for Humacyte and 2 mentions for Contineum Therapeutics. Contineum Therapeutics' average media sentiment score of 1.43 beat Humacyte's score of 1.38 indicating that Contineum Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Contineum Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Humacyte	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Contineum Therapeutics has a beta of 0.7, suggesting that its stock price is 30% less volatile than the broader market. Comparatively, Humacyte has a beta of 2.52, suggesting that its stock price is 152% more volatile than the broader market.

44.7% of Humacyte shares are held by institutional investors. 7.9% of Contineum Therapeutics shares are held by company insiders. Comparatively, 3.1% of Humacyte shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Humacyte has lower revenue, but higher earnings than Contineum Therapeutics. Contineum Therapeutics is trading at a lower price-to-earnings ratio than Humacyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Contineum Therapeutics	$50M	11.10	-$59.98M	-$1.95	N/A
Humacyte	$2.04M	73.68	-$40.83M	-$0.57	N/A

Summary

Humacyte beats Contineum Therapeutics on 10 of the 16 factors compared between the two stocks.

Get Humacyte News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HUMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HUMA vs. The Competition

Export

Metric	Humacyte	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$150.31M	$3.71B	$7.05B	$12.61B
Dividend Yield	N/A	2.20%	2.68%	8.00%
P/E Ratio	-1.19	20.85	27.10	24.26
Price / Sales	73.68	314.01	588.85	117.88
Price / Cash	N/A	61.98	29.22	49.36
Price / Book	33.85	8.49	10.85	6.29
Net Income	-$40.83M	$23.83M	$3.58B	$330.66M
7 Day Performance	-12.18%	-3.56%	-2.12%	-1.35%
1 Month Performance	-35.83%	6.31%	3.27%	-0.64%
1 Year Performance	-72.59%	48.30%	26.33%	19.08%

Humacyte Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HUMA Humacyte	4.2711 of 5 stars	$0.68 -2.1%	$6.25 +823.2%	-70.1%	$150.31M	$2.04M	N/A	150	Positive News Analyst Downgrade
AVTE Aerovate Therapeutics	N/A	$21.51 -1.4%	N/A	+113.3%	$623.47M	N/A	N/A	20	High Trading Volume
ALT Altimmune	2.3336 of 5 stars	$3.08 -2.5%	$15.71 +410.2%	-27.8%	$614.54M	$40K	N/A	50
PROK ProKidney	1.6267 of 5 stars	$1.99 -2.0%	$9.00 +352.3%	-64.5%	$613.18M	$890K	N/A	3	News Coverage
ZSQR Coeptis Therapeutics	0.3674 of 5 stars	$10.99 flat	N/A	-23.5%	$565.23M	$1.36M	N/A	2

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HUMA) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Humacyte (HUMA) Competitors

HUMA vs. AVTE, ALT, PROK, ZSQR, and CTNM

How does Humacyte compare to Aerovate Therapeutics?

Summary

How does Humacyte compare to Altimmune?

Summary

How does Humacyte compare to ProKidney?

Summary

How does Humacyte compare to Coeptis Therapeutics?

Summary

How does Humacyte compare to Contineum Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HUMA vs. The Competition

Humacyte Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Humacyte (HUMA) Competitors

HUMA vs. AVTE, ALT, PROK, ZSQR, and CTNM

How does Humacyte compare to Aerovate Therapeutics?

Which has better valuation and earnings, HUMA or AVTE?

Do insiders & institutionals have more ownership in HUMA or AVTE?

Do analysts prefer HUMA or AVTE?

Is HUMA or AVTE more profitable?

Does the media favor HUMA or AVTE?

Which has more risk and volatility, HUMA or AVTE?

Summary

How does Humacyte compare to Altimmune?

Does the media favor HUMA or ALT?

Do analysts recommend HUMA or ALT?

Which has better earnings and valuation, HUMA or ALT?

Do insiders and institutionals have more ownership in HUMA or ALT?

Is HUMA or ALT more profitable?

Which has more volatility & risk, HUMA or ALT?

Summary

How does Humacyte compare to ProKidney?

Does the media prefer PROK or HUMA?

Which has higher valuation and earnings, PROK or HUMA?

Do insiders and institutionals believe in PROK or HUMA?

Which has more risk & volatility, PROK or HUMA?

Do analysts recommend PROK or HUMA?

Is PROK or HUMA more profitable?

Summary

How does Humacyte compare to Coeptis Therapeutics?

Do insiders & institutionals hold more shares of HUMA or ZSQR?

Does the media refer more to HUMA or ZSQR?

Which has more risk and volatility, HUMA or ZSQR?

Do analysts recommend HUMA or ZSQR?

Which has better earnings & valuation, HUMA or ZSQR?

Is HUMA or ZSQR more profitable?

Summary

How does Humacyte compare to Contineum Therapeutics?

Is CTNM or HUMA more profitable?

Do analysts recommend CTNM or HUMA?

Does the media refer more to CTNM or HUMA?

Which has more volatility and risk, CTNM or HUMA?

Do institutionals and insiders believe in CTNM or HUMA?

Which has higher valuation & earnings, CTNM or HUMA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HUMA vs. The Competition

Humacyte Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools